



Universiteit
Leiden
The Netherlands

Improving acceptance of pharmacogenetic testing in patient care

Bank, P.C.D.

Citation

Bank, P. C. D. (2018, November 14). *Improving acceptance of pharmacogenetic testing in patient care*. Retrieved from <https://hdl.handle.net/1887/66796>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/66796>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/66796> holds various files of this Leiden University dissertation.

Author: Bank, P.C.D.

Title: Improving acceptance of pharmacogenetic testing in patient care

Issue Date: 2018-11-14

Improving acceptance of pharmacogenetic testing in patient care

P.C.D. Bank

The research presented in this thesis was performed at the department of Clinical Pharmacy & Toxicology of the Leiden University Medical Center, Leiden, the Netherlands.

Financial support for the publication of this thesis was provided by the department of Clinical Pharmacy & Toxicology of the Leiden University Medical Center, Leiden, the Netherlands.

The research described in this thesis has been made possible by an unrestricted grant from the Royal Dutch Association for the Advancement of Pharmacy, The Hague, The Netherlands. The study performed in chapter 3 has been performed using GenoChip CYP2D6 kits provided by PharmGenomics GmbH, Mainz, Germany. The research described in chapter 4 was funded by an unrestricted grant from Zorg & Zekerheid, Leiden, The Netherlands and was carried out using DMET Plus arrays provided by Affymetrix, Santa Clara, CA, United States of America.

Cover design	Mai Tran
Layout	Renate Siebes Proefschrift.nu
Printed by	ProefschriftMaken www.proefschriftmaken.nl
ISBN	978-94-92026-15-6

© Paul Bank: Except: Chapter 2: Reproduced with permission from Expert Review of Molecular Diagnostics: Bank et al. 2014 14(6):723-35, Taylor & Francis Group. Chapter 3: Reproduced with permission from Pharmacogenomics: Bank et al. GenoChip CYP2D6 macroarray as a method to genotype for CYP2D6 variants: results of a validation study in a Caucasian population 2015 16(7):681-7, Future Science Group. Chapter 6: Reproduced with permission from Internal and Emergency Medicine, Bank et al. Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase (DPD) splice site variant: the need for further revision of dose and schedule 2014 9(4):481-2, Springer International Publishing AG. Chapter 7: Reproduced with permission from Clinical Pharmacology & Therapeutics: Bank et al. 2018 103(4):599-618, cpt-journal.com. Chapter 8: Reproduced with permission from Pharmacogenomics: Bank et al. A nationwide survey of pharmacists' perception of pharmacogenetics in the context of a clinical decision support system containing pharmacogenetics dosing recommendations 2017 18(3):215-225, Future Science Group. Chapter 9: Reproduced with permission from Pharmacogenomics: Bank et al. 2018 19(4):311-319, Future Science Group. Chapter 10: Reproduced with permission from Advances in Pharmacology: Bank et al. 2018 83:219-246, Elsevier B.V.

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage or retrieval, without permission in writing from the author.

Improving acceptance of pharmacogenetic testing in patient care

Proefschrift

ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof. mr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties
te verdedigen op woensdag 14 november 2018
klokke 10.00 uur

door

Paul Christiaan Dirk Bank

geboren te Heerlen
in 1989

Promotor

Prof. dr. H.-J. Guchelaar

Copromotor

Dr. J.J. Swen

Leden promotiecommissie

Prof. dr. J. Gussekloo

Prof. dr. R.H.N. van Schaik

Erasmus University Medical Center, Rotterdam

Prof. dr. B. Wilffert

University of Groningen, Groningen

Voor pap & mam

*“You inspire me
Like I inspire you”*

Mister And Mississippi - In Between

Contents

Chapter 1	General introduction	11
-----------	----------------------	----

PART I Answers to frequently asked question by clinicians regarding PGx

Chapter 2	Pharmacogenetic biomarkers for predicting drug response	21
-----------	---	----

PART II Implementation of PGx in clinical practice and its impact on a national level

Chapter 3	GenoChip CYP2D6 macroarray as a method to genotype for <i>CYP2D6</i> variants: results of a validation study in a Caucasian population	53
Chapter 4	Implementation of pharmacist initiated pre-emptive pharmacogenetic testing in primary care	67
Chapter 5	Nation-wide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands	85

PART III Harmonization of PGx-test interpretation and therapeutic recommendations

Chapter 6	Fluoropyrimidine toxicity in patients with a dihydropyrimidine dehydrogenase (DPD) splice site variant: the need for further revision of dose and schedule	109
Chapter 7	Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group	125

PART IV Knowledge, experience and attitudes towards PGx of pharmacists and pharmacy students

Chapter 8	A nationwide survey of pharmacists' perception of pharmacogenetics in the context of a clinical decision support system containing pharmacogenetics dosing recommendations	165
Chapter 9	A nationwide cross-sectional survey of pharmacy students on knowledge, experience, and attitudes towards pharmacogenetic testing in the Netherlands	207

PART V General discussion & Summary

Chapter 10	General discussion	243
Chapter 11	English summary	269
	Nederlandse samenvatting	279
	About the author	289
	Dankwoord	295

